Anti-malaria MAb in Malian Children (L9LS)

• ClinicalTrials.gov Identifier: NCT05304611
• Recruitment Status: Recruiting
• First Posted: March 31, 2022
• Last Update Posted: February 15, 2023
• Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Collaborators: National Institutes of Health (NIH); Vaccine Research Center (VRC); Malaria Research and Training Center (MRTC); Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS/FAPH); University of Sciences, Techniques, & Technologies of Bamako (USTTB); University of Washington; Harvard School of Public Health (HSPH); Indiana University School of Medicine, Indiana University
• Information provided by (Responsible Party): National Institute of Allergy and Infectious Diseases (NIAID)

Study Description

Brief Summary:

The purpose of this study is to evaluate the safety and tolerability of onetime subcutaneous (SC) or intravenous (IV) administration of monoclonal antibody (MAb) L9LS in healthy Malian adults and one-time SC administration of L9LS in healthy Malian children, as well as its protective efficacy against naturally occurring Plasmodium falciparum (Pf) infection over a 7-month malaria season in healthy Malian children 6-10 years of age.

Condition or disease	Intervention/treatment	Phase
Plasmodium Falciparum Infection; Malaria	Biological: L9LS (VRC-MALMAB0114-00-AB); Other: Normal saline	Phase 2

Detailed Description:

A two-part, phase 2 trial evaluating the safety and tolerability of onetime subcutaneous (SC) or intravenous (IV) administration of monoclonal antibody (MAb) L9LS in healthy Malian adults and one-time SC administration of L9LS in healthy Malian children, as well as its protective efficacy against naturally occurring Plasmodium falciparum (Pf) infection over a 7-month malaria season in healthy Malian children 6-10 years of age.

The first part of the study is an age de-escalation and dose-escalation study for safety and tolerability. Adult subjects in the dose-escalation study will be assigned in open-label fashion to 1 of 3 L9LS dose arms. Dosing will begin in the lowest dose arm. Once all subjects in that arm reach day 7 post-administration, if no safety concerns have arisen, dosing will begin at the next dose level. Once all subjects in that arm reach day 7 post-administration, if no safety concerns have arisen, dosing will begin at the highest dose level. Once all adult subjects reach day 7 post-administration, if no safety concerns have arisen, 18 subjects aged 6-10 years will be randomized 1:1 to L9LS or placebo in double-blind fashion. Once all 18 subjects reach day 7 post-administration, if no safety concerns have arisen, an additional 18 subjects aged 6-10 years will be randomized 1:1 to L9LS versus placebo. Randomization of subjects aged 6-10 years in each L9LS dose arm will be weight-stratified and enrollment will be weight de-escalated. Adult subjects will be followed for safety to assess adverse events (AEs) at study visits 1, 3, 7, 14, 21, and 28 days after administration, and once every month thereafter through 28 weeks. Subjects aged 6-10 years will be followed at study visits 1, 3, 7, 14, 21, and 28 days after administration, and once every 2 weeks thereafter through 28 weeks. Primary study assessments include physical examination and blood collection for identification of Pf infection and other research laboratory evaluations. After the last subject in the pediatric L9LS dose arm reaches day 7 safety follow-up, an interim safety evaluation will be performed before enrollment begins for the efficacy part of the study. Data from the 36 subjects aged 6-10 years enrolled in the dose-escalation study will be included in a secondary analysis to determine the relationship between L9LS concentration and the risk of Pf infection.

The second part of the study is a weight-stratified, randomized, double-blind, placebo-controlled trial to assess safety and protective efficacy of L9LS versus placebo administered SC in children 6-10 years of age. In this part of the study, subjects will be randomized to L9LS or placebo. Randomization of subjects in each arm will be weight-stratified. Subjects in the efficacy study will receive the study agent prior to the malaria season and be followed at study visits 1, 3, 7, 14, 21, and 28 days later, and once every 2 weeks thereafter through 28 weeks. Primary study assessments include physical examination and blood collection for identification of Pf infection and other research laboratory evaluations.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 279 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Prevention
• Official Title: Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium Falciparum, in a Dose-Escalation Trial in Adults and Children and a Randomized, Double-Blind Trial of Children in Mali
• Actual Study Start Date: March 18, 2022
• Estimated Primary Completion Date: March 2024
• Estimated Study Completion Date: March 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Adult Dose-escalation study: Arm 1: 300 mg of L9LS; Participants will receive 300 mg SC of L9LS. Once subjects reach day 7 post-administration without safety concerns dosing will begin for arm 2.	Biological: L9LS (VRC-MALMAB0114-00-AB); Administered one time via subcutaneous route.
Experimental: Adult Dose-escalation study: Arm 2: 600 mg of L9LS; Participants will receive 600 mg SC of L9LS. Once subjects reach day 7 post-administration without safety concerns dosing will begin for arm 3.	Biological: L9LS (VRC-MALMAB0114-00-AB); Administered one time via subcutaneous route.
Experimental: Adult Dose-escalation study: Arm 3: 20 mg/kg of L9LS; Participants will receive highest dose of 20 mg/kg IV of L9LS. Once subjects reach day 7 post-administration without safety concerns dosing will begin for subjects aged 6 -10 years.	Biological: L9LS (VRC-MALMAB0114-00-AB); Administered one time via subcutaneous route.
Experimental: Subject 6-10 years Dose-escalation study: Arm 1: 150 mg of L9LS; Subjects age 6-10 years will receive 150 mg of L9LS SC. Once subjects reach day 7 post-administration without safety concerns, will begin arm 2.	Biological: L9LS (VRC-MALMAB0114-00-AB); Administered one time via subcutaneous route.
Experimental: Subject 6-10 years Dose-escalation study: Arm 2: 300 mg of L9LS; Subjects age 6-10 years will receive 300 mg of L9LS SC. Once subjects reach day 7 post-administration without safety concerns, will begin weight de-escalation.	Biological: L9LS (VRC-MALMAB0114-00-AB); Administered one time via subcutaneous route.
Placebo Comparator: Subject 6-10 years Dose-escalation study: Arm 3: Placebo; Half of subjects age 6-10 will receive placebo of Normal Saline for comparison.	Other: Normal saline; Administered one time via subcutaneous or intravenous administration.
Experimental: Efficacy study: Arm 1: 150 mg of L9LS; 75 children age 6-10 will receive 150 mg of L9LS.	Biological: L9LS (VRC-MALMAB0114-00-AB); Administered one time via subcutaneous route.
Experimental: Efficacy study: Arm 2: 300 mg of L9LS; 75 children age 6-10 will receive 300 mg of L9LS.	Biological: L9LS (VRC-MALMAB0114-00-AB); Administered one time via subcutaneous route.
Placebo Comparator: Efficacy study: Arm 3: Placebo; 75 children age 6-10 will receive normal saline placebo.	Other: Normal saline; Administered one time via subcutaneous or intravenous administration.

Outcome Measures

Primary Outcome Measures :

1. Incidence of local AEs occurring within 7 days after the administration of L9LS [ Time Frame: Measured through Day 7 ]
   Dose escalation and efficacy study
2. Severity of local AEs occurring within 7 days after the administration of L9LS [ Time Frame: Measured through Day 7 ]
   Dose escalation and efficacy study
3. Incidence of systemic AEs occurring within 7 days after the administration of L9LS [ Time Frame: Measured through Day 7 ]
   Dose escalation and efficacy study
4. Severity of systemic AEs occurring within 7 days after the administration of L9LS [ Time Frame: Measured through Day 7 ]
   Dose escalation and efficacy study
5. Occurrence of Plasmodium falciparum (Pf) blood stage infection [ Time Frame: Measured through Week 28 ]
   Detected by microscopic examination of thick blood smear for 28 weeks after administration of L9LS or placebo. Efficacy study only.

Secondary Outcome Measures :

1. Measurement of L9LS in sera of recipients. [ Time Frame: Measured through Week 28 ]
   Dose escalation and efficacy study
2. Pf blood-stage infection as detected by Reverse Transcription Polymerase Chain Reaction (RT-PCR) after administration of L9LS or placebo. [ Time Frame: Measured through Week 28 ]
   Dose escalation and efficacy study
3. Incidence of clinical malaria after administration of L9LS or placebo. [ Time Frame: Measured through Week 28 ]
   Dose escalation and efficacy study
4. Individual subject non compartmental Pharmacokinetic (PK) analysis-the maximum concentration (Cmax). [ Time Frame: Measured through Week 28 ]
   Dose escalation and efficacy study
5. Individual subject non compartmental PK analysis measure by time of maximal concentration (Tmax). [ Time Frame: Measured through Week 28 ]
   Dose escalation and efficacy study
6. Individual subject non compartmental PK analysis measured by area under the concentrations vs. time curve (AUC). [ Time Frame: Measured through Week 28 ]
   Dose escalation and efficacy study
7. Individual subject non compartmental PK analysis measured by time weighted average concentrations (Cave). [ Time Frame: Measured through Week 28 ]
   Dose escalation and efficacy study
8. Population PK analyses measured by clearance (CL). [ Time Frame: Measured through Week 28 ]
   Dose escalation and efficacy study
9. Population PK analysis measured by central and peripheral volumes of distribution (Vd1 and Vd2). [ Time Frame: Measured through Week 28 ]
   Dose escalation and efficacy study
10. Population PK analysis measured by intercompartmental clearance (Q). [ Time Frame: Measured through Week 28 ]
    Dose escalation and efficacy study
11. Population PK analysis measure by total volume of distribution at steady-state (Vdss). [ Time Frame: Measured through Week 28 ]
    Dose escalation and efficacy study

Eligibility Criteria

• Ages Eligible for Study: 6 Years to 55 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Is within the appropriate age range for the respective cohort:

  1. Children: Aged ≥6 years and <11 years.
  2. Adults: Aged ≥18 years.
• Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
• In good general health and without clinically significant medical history.
• Adult participants or parent and/or guardian of minor participants able to provide informed consent.
• Willing to have blood samples and data stored for future research.
• Resides in or near Kalifabougou or Torodo, Mali, and available for the duration of the study.

• For the adult cohort, females of childbearing potential must be willing to use reliable contraception from 21 days prior to study day 0 through the final study visit as described below.

  • Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device.
  • Nonchildbearing women will be required to report date of last menstrual period, history of surgical sterility (i.e., tubal ligation, hysterectomy) or premature ovarian insufficiency, and will have urine or serum pregnancy test performed per protocol.

Exclusion Criteria:

• Body weight <15 kg or >30 kg for children, or >60 kg for adults.
• Currently receiving or planning to receive seasonal malaria chemoprevention (SMC).
• Any history of menses (for 6-10 year old cohort) or positive pregnancy test at screening (for adult cohort).
• Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol.
• Subject (for adult subjects) or parental (for minor subjects) study comprehension examination score of <80% correct or per investigator discretion.
• Hemoglobin, white blood cell, absolute neutrophil, or platelet count outside the local laboratory-defined limits of normal. (Subjects may be included at the investigator's discretion for "not clinically significant" values.)
• Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of normal. (Subjects may be included at the investigator's discretion for "not clinically significant" values.)
• Infected with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).
• Known or documented sickle cell disease by history. (Note: Known sickle cell trait is NOT exclusionary.)
• Clinically significant abnormal electrocardiogram (ECG; Corrected QT Interval (QTc) >460 or other significant abnormal findings, including unexplained tachycardia or bradycardia).
• Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.
• Receipt of any investigational product within the past 30 days.
• Participation or planned participation in an interventional trial with an investigational product before the last required protocol visit. (Note: Past, current, or planned participation in observational studies is NOT exclusionary.)
• Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
• History of a severe allergic reaction or anaphylaxis.
• Severe asthma (defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years).
• Salivary gland disorder diagnosed by a doctor (e.g., parotitis, sialadenitis, sialolithiasis, salivary gland tumors).
• Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, or autoimmune thrombocytopenia.
• Known immunodeficiency syndrome.
• Known asplenia or functional asplenia.
• Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone >10 mg/day) or immunosuppressive drugs within 30 days of day 0.
• Receipt of a live vaccine within the past 4 weeks or a killed vaccine or COVID-19 vaccine within the past 2 weeks prior to study agent administration.
• Receipt of immunoglobulins and/or blood products within the past 6 months.
• Previous receipt of an investigational malaria vaccine or monoclonal antibody in the last 5 years.
• Known allergies or contraindication against artemether-lumefantrine.
• Clinical signs of malnutrition.
• Other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or render the subject unable to comply with the protocol.

Contacts and Locations

Contacts

Contact: Kassoum Kayentao, MD, MPH, PhD; +223 7646 0173; kayentao@icermali.org

Contact: Boubacar Traore, PharmD, PhD; +223 2022 8109; bouba.traore@mrtcbko.org

Locations

Mali

Kalifabougou MRTC Clinic; Recruiting

Kalifabougou, Région De Koulikoro, Mali

Contact: Kassoum Kayentao, MD, MPH, PhD +223 7646 0173 kayentao@icermali.org

Torodo MRTC Clinic; Not yet recruiting

Torodo, Région De Koulikoro, Mali

Contact: Kassoum Kayentao, MD, MPH, PhD +223 7646 0173 kayentao@icermali.org

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

National Institutes of Health (NIH)

Vaccine Research Center (VRC)

Malaria Research and Training Center (MRTC)

Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS/FAPH)

University of Sciences, Techniques, & Technologies of Bamako (USTTB)

University of Washington

Harvard School of Public Health (HSPH)

Indiana University School of Medicine, Indiana University

Investigators

• Principal Investigator: Kassoum Kayentao, MD, MPH, PhD; Faculté de Médecine Pharmacie d'Odontostomatologie (FMPOS)
• Principal Investigator: Peter Crompton, MD, MPH; National Institutes of Health (NIH)

More Information

• Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
• ClinicalTrials.gov Identifier: NCT05304611
• Other Study ID Numbers: 2022/34/CE/USTTB
• First Posted: March 31, 2022
• Last Update Posted: February 15, 2023
• Last Verified: February 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Malaria; Protozoan Infections; Parasitic Diseases; Infections; Vector Borne Diseases